4.3 Article

Toll-like receptor 2 suppresses Toll-like receptor 9 responses in Peyer's patch dendritic cells

Journal

IMMUNOBIOLOGY
Volume 220, Issue 6, Pages 734-743

Publisher

ELSEVIER GMBH, URBAN & FISCHER VERLAG
DOI: 10.1016/j.imbio.2014.12.022

Keywords

Dendritic cells; Interleukin-12; Interleukin-23; Intestinal immunity; Peyer's patches; Toll-like receptors

Categories

Funding

  1. Japan Society for the Promotion of Science (JSPS) [23380073]
  2. Grants-in-Aid for Scientific Research [26292065, 23228003] Funding Source: KAKEN

Ask authors/readers for more resources

In the intestine, immune responses to commensal microbes should be regulated precisely. This regulation is achieved partly by dendritic cells (DCs), which recognize microbes through Toll-like receptors (TLRs). Although TLR responses have been intensely studied, cross-talk between individual TLRs remains unclear. The present study shows that TLR2 suppressed TLR9-induced Il12b gene expression and subsequent interleukin (IL)-12 and IL-23 production in DCs from Peyer's patch, a lymphoid tissue in the small intestine. The DCs expressed Il12b gene and produced IL-12 and IL-23 in response to TLR9 stimulation, and these responses were suppressed when the DCs were stimulated simultaneously with TLR2. The suppression was also observed in the non-intestinal DCs, such as spleen DCs and bone marrow-derived DCs. Peyer's patch DCs expressed Il12b gene also in response to TLR7 or CD40 stimulation, but these responses were not suppressed by simultaneous TLR2 stimulation. In addition, TLR9-induced Tnf and Il6 gene expression was not suppressed by TLR2. Furthermore, the supernatant of TLR2-stimulated DCs could not suppress TLR9-induced Il12b gene expression. These results suggest that TLR2 suppress TLR9-induced responses selectively, and this suppression is not mediated by secretory factors. The suppressive TLR cross-talk might play a certain role in preventing excess inflammatory responses to commensal microbes in the intestine and may have implications for the therapeutic strategies for intestinal inflammatory diseases, autoimmune diseases and cancer. (C) 2015 Elsevier GmbH. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

Mesenteric lymph node CD11b- CD103+ PD-L1High dendritic cells highly induce regulatory T cells

Aya Shiokawa, Ryutaro Kotaki, Tomohiro Takano, Haruyo Nakajima-Adachi, Satoshi Hachimura

IMMUNOLOGY (2017)

Article Hematology

Imbalanced expression of polycistronic miRNA in acute myeloid leukemia

Ryutaro Kotaki, Hiroshi Higuchi, Daisuke Ogiya, Yasuhiro Katahira, Natsumi Kurosaki, Naoko Yukihira, Jun Ogata, Haruna Yamamoto, Syakira Mohamad Alba, Azran Azhim, Tatsuo Kitajima, Shigeaki Inoue, Kazuhiro Morishita, Koh Ono, Ryo Koyama-Nasu, Ai Kotani

INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)

Article Immunology

SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine

Ryutaro Kotaki, Yu Adachi, Saya Moriyama, Taishi Onodera, Shuetsu Fukushi, Takaki Nagakura, Keisuke Tonouchi, Kazutaka Terahara, Lin Sun, Tomohiro Takano, Ayae Nishiyama, Masaharu Shinkai, Kunihiro Oba, Fukumi Nakamura-Uchiyama, Hidefumi Shimizu, Tadaki Suzuki, Takayuki Matsumura, Masanori Isogawa, Yoshimasa Takahashi

Summary: Multiple SARS-CoV-2 variants, particularly Beta and Omicron, have the potential to evade neutralizing antibodies, even in those who have received two doses of the BNT162b2 mRNA vaccine. However, boosting with a third vaccine dose or breakthrough infection can improve the overall breadth of neutralizing antibodies. This study longitudinally profiles the cellular composition of RBD-binding memory B cell subsets and their antibody binding and neutralizing activity after the second dose of mRNA vaccine. It finds that two doses of mRNA vaccine induce an expanded antibody breadth over time, while a subset of resting memory B cells show the ability to produce Beta and Omicron-neutralizing antibodies.

SCIENCE IMMUNOLOGY (2022)

Article Immunology

Recall of B cell memory depends on relative locations of prime and boost immunization

Masayuki Kuraoka, Chen-Hao Yeh, Goran Bajic, Ryutaro Kotaki, Shengli Song, Ian Windsor, Stephen C. Harrison, Garnett Kelsoe

Summary: Immunization or microbial infection can establish long-term B cell memory both systemically and locally. Local B cell memory contributes to early local plasmacytic responses and recall germinal center (GC) reactions. The efficacy of recall GCs depends on the locality of immunization, and local boosts are more efficient at recruiting progeny of primary GC B cells. Additionally, local boosts lead to elevated levels of immunoglobulin mutation and higher avidity B cell antigen receptors (BCRs) in recall GCs. The importance of locality in humoral immunity and its implications for vaccination strategies are highlighted.

SCIENCE IMMUNOLOGY (2022)

Article Multidisciplinary Sciences

Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain

Tomohiro Takano, Takashi Sato, Ryutaro Kotaki, Saya Moriyama, Shuetsu Fukushi, Masahiro Shinoda, Kiyomi Kabasawa, Nagashige Shimada, Mio Kousaka, Yu Adachi, Taishi Onodera, Kazutaka Terahara, Masanori Isogawa, Takayuki Matsumura, Masaharu Shinkai, Yoshimasa Takahashi

Summary: Takano et al. demonstrate that a heterologous booster using a SARS-CoV-2 recombinant spike protein vaccine induces a more sustained and broader anti-spike receptor-binding domain antibody response compared to a homologous booster using an mRNA vaccine. The study shows that the S-268019-b spike protein booster generates higher and longer-lasting IgG titers specific to the SARS-CoV-2 spike receptor-binding domain, with the ability to bind to antigenically distinct variants, while the BNT162b2 mRNA homologous booster has a weaker effect. Additionally, the S-268019-b booster enhances the production of RBD-angiotensin-converting enzyme 2 (ACE2) binding inhibitory antibodies, resulting in increased neutralizing activities against Omicron BA.1 and BA.5 variants.

NATURE COMMUNICATIONS (2023)

Article Multidisciplinary Sciences

CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes

Taishi Onodera, Nicolas Sax, Takashi Sato, Yu Adachi, Ryutaro Kotaki, Takeshi Inoue, Ryo Shinnakasu, Takayuki Nakagawa, Shuetsu Fukushi, Tommy Terooatea, Mai Yoshikawa, Keisuke Tonouchi, Takaki Nagakura, Saya Moriyama, Takayuki Matsumura, Masanori Isogawa, Kazutaka Terahara, Tomohiro Takano, Lin Sun, Ayae Nishiyama, Shinnya Omoto, Masaharu Shinkai, Tomohiro Kurosaki, Kazuo Yamashita, Yoshimasa Takahashi

Summary: By analyzing single Bmem cells and assessing antibody function, we have identified the characteristics of Bmem cells that carry potent neutralizing antibodies in COVID-19 convalescent individuals. These neutralizing antibodies are marked by elevated CD62L expression, distinct epitope preference, and usage of convergent VH genes, which contribute to their neutralizing activities. Despite equivalent receptor binding, there is a correlation between neutralizing antibody titers and the CD62L+ subset. Moreover, the dynamics of the CD62L+ subset differ among patients with varying COVID-19 severities. Our Bmem cell profiling reveals the unique phenotype of the subset harboring potent neutralizing BCRs and enhances our understanding of humoral protection.

SCIENCE ADVANCES (2023)

Article Multidisciplinary Sciences

Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants

Saya Moriyama, Yuki Anraku, Shunta Taminishi, Yu Adachi, Daisuke Kuroda, Shunsuke Kita, Yusuke Higuchi, Yuhei Kirita, Ryutaro Kotaki, Keisuke Tonouchi, Kohei Yumoto, Tateki Suzuki, Taiyou Someya, Hideo Fukuhara, Yudai Kuroda, Tsukasa Yamamoto, Taishi Onodera, Shuetsu Fukushi, Ken Maeda, Fukumi Nakamura-Uchiyama, Takao Hashiguchi, Atsushi Hoshino, Katsumi Maenaka, Yoshimasa Takahashi

Summary: In this study, RBS antibodies resistant to Omicron mutations were selected. Y489 was identified as a vulnerable site and a common marker of broadly neutralizing antibodies. A computationally designed antibody, NIV-10/FD03, showed the ability to bind and neutralize viruses with the 486 mutation.

NATURE COMMUNICATIONS (2023)

No Data Available